Frequency touts first-in-human safety study for hearing loss therapy

Frequency Therapeutics has finished a first-in-human study of its progenitor cell activation therapy, FX-322, in nine adults with severe to profound sensorineural hearing loss.

The company’s candidate is a combination of small molecules that are designed to activate progenitor cells and trigger the formation of new hair cells in the inner ear.

Get the full story at our sister site, Drug Delivery Business News.

The post Frequency touts first-in-human safety study for hearing loss therapy appeared first on MassDevice.

from MassDevice http://ift.tt/2qeRsvp